KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Tax Provisions (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Tax Provisions for 11 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Tax Provisions fell 80.43% to $2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$10.5 million, a 143.87% decrease, with the full-year FY2025 number at -$10.5 million, down 143.66% from a year prior.
  • Tax Provisions was $2.2 million for Q4 2025 at Supernus Pharmaceuticals, up from -$12.8 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $25.9 million in Q3 2023 to a low of -$16.3 million in Q2 2023.
  • A 5-year average of $1.7 million and a median of $2.8 million in 2022 define the central range for Tax Provisions.
  • Peak YoY movement for Tax Provisions: plummeted 570.28% in 2023, then soared 7586.39% in 2024.
  • Supernus Pharmaceuticals' Tax Provisions stood at -$391000.0 in 2021, then skyrocketed by 2572.12% to $9.7 million in 2022, then tumbled by 101.52% to -$147000.0 in 2023, then skyrocketed by 7586.39% to $11.0 million in 2024, then tumbled by 80.43% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Tax Provisions are $2.2 million (Q4 2025), -$12.8 million (Q3 2025), and -$5.8 million (Q2 2025).